EGFR and non-small cell lung carcinoma: For instance, MET amplification has been proven to be the mechanism of primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in EGFR-mutant non-small cell lung cancer (NSCLC) patients.